GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
May 20, 2024 08:45 ET | GRI Bio, Inc.
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score...
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 14, 2024 16:05 ET | Serina Therapeutics, Inc.
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
May 06, 2024 11:00 ET | Imunon, Inc.
LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
May 06, 2024 08:00 ET | Processa Pharmaceuticals, Inc.
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
May 01, 2024 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with...
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
April 29, 2024 08:45 ET | GRI Bio, Inc.
LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
April 17, 2024 16:05 ET | Serina Therapeutics, Inc.
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE...
IMUNON Reports Compliance with Nasdaq Listing Requirements
April 11, 2024 08:00 ET | Imunon, Inc.
LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated...
Logo edited.jpg
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
March 13, 2024 06:00 ET | Greenwich LifeSciences, Inc.
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
IMUNON Announces Leadership Change
March 12, 2024 17:00 ET | Imunon, Inc.
Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged.  LAWRENCEVILLE, N.J., March 12, 2024 ...